JUNZHENG(SH:601216)2021-10-28 16:00Financial Performance - The company's operating revenue for Q3 2021 reached ¥4,712,937,803.28, representing a year-on-year increase of 34.20%[5] - The net profit attributable to shareholders for Q3 2021 was ¥995,617,248.07, up 31.05% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥954,061,129.23, reflecting a 24.13% increase year-on-year[5] - The basic earnings per share for Q3 2021 was ¥0.1180, an increase of 31.05% compared to the same period last year[5] - The company reported a 54.93% increase in net profit attributable to shareholders for the year-to-date period compared to the same period last year, driven by higher product prices and increased gross profit[10] - Total operating revenue for the first three quarters of 2021 reached CNY 13,387,518,499.60, an increase of 25.7% compared to CNY 10,705,471,847.86 in the same period of 2020[27] - Net profit for Q3 2021 was CNY 3,255,278,184.79, up 55.8% from CNY 2,091,013,641.29 in Q3 2020[29] - Operating profit for Q3 2021 was CNY 3,827,383,457.33, significantly higher than CNY 2,446,128,389.06 in Q3 2020, marking a growth of 56.4%[29] - The total comprehensive income for the period reached ¥3,199,234,108.08, a significant increase from ¥2,026,810,200.79 in the previous year, reflecting a growth of approximately 57.7%[31] - Basic and diluted earnings per share increased to ¥0.3828, compared to ¥0.2471 in the same period last year, representing a growth of 54.8%[31] Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥34,872,623,564.69, which is a 3.54% increase from the end of the previous year[5] - As of September 30, 2021, the company's total assets amounted to approximately ¥34.87 billion, an increase from ¥33.68 billion at the end of 2020, representing a growth of about 3.4%[23][24] - The company's current assets decreased to approximately ¥9.49 billion from ¥10.29 billion, a decline of about 7.7% year-over-year[23] - The total liabilities of the company were approximately ¥9.48 billion, compared to ¥8.29 billion at the end of 2020, representing an increase of about 14.4%[24] - The total liabilities increased to CNY 12,974,568,210.55, compared to CNY 12,476,474,871.58 in the previous year, reflecting a growth of 4.0%[26] - The total non-current liabilities increased to CNY 4,809,034,307.44, compared to CNY 3,153,861,736.02 in the previous year, indicating a growth of 52.5%[26] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥3,872,994,409.01, showing a significant increase of 53.96% year-on-year[5] - Cash flow from operating activities generated a net amount of ¥3,872,994,409.01, up from ¥2,515,658,007.38, indicating a year-over-year increase of 54%[32] - Cash inflow from investment activities totaled ¥7,307,798,055.64, while cash outflow was ¥7,804,258,822.02, resulting in a net cash flow of -¥496,460,766.38, contrasting sharply with a positive cash flow of ¥8,089,812,266.89 in the previous year[32] - The net cash flow from financing activities was -¥5,474,654,132.44, slightly improved from -¥5,531,912,382.18 in the same period last year[33] - The cash and cash equivalents at the end of the period stood at ¥1,960,434,684.64, down from ¥5,939,059,356.98 at the end of the previous year, indicating a decrease of approximately 66.9%[33] Shareholder Information - The company has a total of 294,594 common shareholders at the end of the reporting period[11] - The top shareholder, Du Jiangtao, holds 2,695,680,000 shares, accounting for 31.95% of the total shares[11] Strategic Decisions - The company has terminated its acquisition plans for Beijing Bohui Innovation Biotechnology Group due to uncertainties caused by the COVID-19 pandemic[19][20] - The company’s board approved the termination of the asset sale and cash subscription agreement with Bohui Innovation, reflecting a strategic shift in its investment approach[19][20] Research and Development - Research and development expenses for the first three quarters were CNY 158,953,769.30, slightly down from CNY 161,929,510.19 in the same period last year[27] Other Financial Metrics - The weighted average return on equity for Q3 2021 was 4.79%, an increase of 0.55 percentage points compared to the previous year[5] - The company reported a decrease in interest income to CNY 52,162,956.19 in Q3 2021, down from CNY 88,384,470.34 in Q3 2020[29] - Other comprehensive income after tax for Q3 2021 was reported at CNY -56,044,076.71, compared to CNY -64,203,440.50 in Q3 2020, showing an improvement[29] - The company reported a decrease in cash received from other operating activities to ¥259,564,316.61 from ¥322,573,698.50, a decline of about 19.5%[32] - The company received cash from operating activities amounting to ¥11,285,232,658.20, compared to ¥9,546,241,100.03 in the previous year, marking an increase of 18.2%[32]